메뉴 건너뛰기
Nature Reviews Cardiology
Volumn 10, Issue 1, 2013, Pages 1-
Lipids: Antibodies against PCSK9-a new era of therapy

(1)  King, Alexandra a  

a NONE
Author keywords

[No Author keywords available]
Indexed keywords

ALIROCUMAB; AMG 145; ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISINKEXIN TYPE 9 PROTEIN; SUBTILISIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;
EID: 84871780432     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.166     Document Type: Note
Times cited : (10)
References (5)
  • 1
    • 84869220345 scopus 로고    scopus 로고
    • Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial
    • Original articles Raal, F et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126, 2408-2417 (2012)
    • (2012) Circulation , vol.126 , pp. 2408-2417
    • Raal, F.1
  • 2
    • 84871326497 scopus 로고    scopus 로고
    • Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial
    • doi:10.1001/jama.2012.25790
    • Sullivan, D. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA doi:10.1001/jama.2012.25790
    • JAMA
    • Sullivan, D.1
  • 3
    • 84870478439 scopus 로고    scopus 로고
    • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study
    • doi:10.1016/S0140-6736(12)61770-X
    • Giugliano, R. P. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet doi:10.1016/S0140-6736(12)61770-X
    • Lancet
    • Giugliano, R.P.1
  • 4
    • 84870494510 scopus 로고    scopus 로고
    • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study
    • doi:10.1016/S0140-6736(12)61771-1
    • Koren, M. J. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet doi:10.1016/S0140-6736(12)61771-1
    • Lancet
    • Koren, M.J.1
  • 5
    • 84868689211 scopus 로고    scopus 로고
    • Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia
    • doi:10.1056/NEJMoa1201832
    • Roth, E. M. et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. doi:10.1056/NEJMoa1201832
    • N. Engl. J. Med
    • Roth, E.M.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.